Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2022 Mar 1:2021.12.23.21268272.
doi: 10.1101/2021.12.23.21268272.

Population immunity to pre-Omicron and Omicron SARS-CoV-2 variants in US states and counties through December 1, 2021

Affiliations

Population immunity to pre-Omicron and Omicron SARS-CoV-2 variants in US states and counties through December 1, 2021

Fayette Klaassen et al. medRxiv. .

Update in

Abstract

Prior infection and vaccination both contribute to population-level SARS-CoV-2 immunity. We used a Bayesian model to synthesize evidence and estimate population immunity to prevalent SARS-CoV-2 variants in the United States over the course of the epidemic until December 1, 2021, and how this changed with the introduction of the Omicron variant. We used daily SARS-CoV-2 infection estimates and vaccination coverage data for each US state and county. We estimated relative rates of vaccination conditional on previous infection status using the Census Bureau’s Household Pulse Survey. We used published evidence on natural and vaccine-induced immunity, including waning and immune escape. The estimated percentage of the US population with a history of SARS-CoV-2 infection or vaccination as of December 1, 2021, was 88.2% (95%CrI: 83.6%-93.5%), compared to 24.9% (95%CrI: 18.5%-34.1%) on January 1, 2021. State-level estimates for December 1, 2021, ranged between 76.9% (95%CrI: 67.6%-87.6%, West Virginia) and 94.4% (95%CrI: 91.2%-97.3%, New Mexico). Accounting for waning and immune escape, the effective protection against the Omicron variant on December 1, 2021, was 21.8% (95%CrI: 20.7%-23.4%) nationally and ranged between 14.4% (95%CrI: 13.2%-15.8%, West Virginia), to 26.4% (95%CrI: 25.3%-27.8%, Colorado). Effective protection against severe disease from Omicron was 61.2% (95%CrI: 59.1%-64.0%) nationally and ranged between 53.0% (95%CrI: 47.3%-60.0%, Vermont) and 65.8% (95%CrI: 64.9%-66.7%, Colorado). While over three-quarters of the US population had prior immunological exposure to SARS-CoV-2 via vaccination or infection on December 1, 2021, only a fifth of the population was estimated to have effective protection to infection with the immune-evading Omicron variant.

Significance: Both SARS-CoV-2 infection and COVID-19 vaccination contribute to population-level immunity against SARS-CoV-2. This study estimates the immunity and effective protection against future SARS-CoV-2 infection in each US state and county over 2020-2021. The estimated percentage of the US population with a history of SARS-CoV-2 infection or vaccination as of December 1, 2021, was 88.2% (95%CrI: 83.6%-93.5%). Accounting for waning and immune escape, protection against the Omicron variant was 21.8% (95%CrI: 20.7%-23.4%). Protection against infection with the Omicron variant ranged between 14.4% (95%CrI: 13.2%-15.8%%, West Virginia) and 26.4% (95%CrI: 25.3%-27.8%, Colorado) across US states. The introduction of the immune-evading Omicron variant resulted in an effective absolute increase of approximately 30 percentage points in the fraction of the population susceptible to infection.

PubMed Disclaimer

Conflict of interest statement

Competing interest statement: VEP has received reimbursement from Merck and Pfizer for travel expenses to Scientific Input Engagements unrelated to the topic of this manuscript. All other authors have declared that no competing interest exist.

Figures

Figure 1:
Figure 1:
Estimated percentage immunologically exposed on December 1, 2021, for each US county and state. Footnote: The background coloring indicates the state-specific distribution of immunity as a function of infections and vaccinations. Black dots represent counties in a state, red dots the state average. The orange diamond represents the state-population-weighted national averages of the percentage ever infected and vaccinated (this does not represent the national average of immunity because the calculation for immunity is state-specific).
Figure 2:
Figure 2:
State-level estimates and uncertainty intervals of the percentage immunologically exposed, effectively protected against infection, and effectively protected against severe disease over time, with estimates of effective protection against Omicron infection under three immune escape scenarios.
Figure 3:
Figure 3:
County-level estimates of the percentage of the population effectively protected against infection at four time-points between January 31, 2021 and December 1, 2021.
Figure 4:
Figure 4:
Relative contribution of prior infection and vaccination to population immunity for each county at four time-points between January 31, 2021 and December 1, 2021. Footnote: The percentage ever infected and the percentage vaccinated are categorized with cut-off scores of 40%, 50% and 60%. These values which roughly corresponds to the quantile breakpoints of the estimates of ever infected and vaccinated on December 1, 2021.

References

    1. The New York Times. Coronavirus in the U.S.: Latest Map and Case Count. https://www.nytimes.com/interactive/2021/us/covid-cases.html. Published 2021. Accessed November 1, 2021, 2021.
    1. Washington Post. U.S. coronavirus cases and state maps: tracking cases, deaths. https://www.washingtonpost.com/graphics/2020/national/coronavirus-us-cas.... Published 2021. Accessed November 1, 2021, 2021.
    1. The COVID Tracking Project. https://covidtracking.com/. Accessed October 29, 2021.
    1. Kawohl W, Nordt C. COVID-19, unemployment, and suicide. Lancet Psychiatry. 2020;7(5):389–390- 389–390. 10.1016/s2215-0366(20)30141-3 - DOI - PMC - PubMed
    1. Baig AS, Butt HA, Haroon O, Rizvi SAR. Deaths, panic, lockdowns and US equity markets: The case of COVID-19 pandemic. Finance Research Letters. 2021;38:101701–101701. 10.1016/j.frl.2020.101701 - DOI - PMC - PubMed

Publication types